Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

According to the report: u   p to 75% of women will have at least one vaginal yeast infection in their life

- A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, will reach over USD 2 billion by 2030, with a compound annual growth rate of 5.25% globally and 3.9% in North America and 4.2% in Europe .

Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

The analysis emphasis that up to 75% of women will have at least one vaginal yeast infection in their life, Moreover, recurrent VVC (Vulvovaginal Candidiasis) affects nearly 8% of women globally (for women above the ages of 15-60). According to the data, 100% of women with Recurrent VVC will purchase a combination of over-the-counter and prescription antifungal treatments, usually with the common use of oral agents. Compared to women with non-recurrent VCC, 55.2% will purchase prescription antifungal treatment, 37% over-the-counter antifungal, 5.6% will purchase a combination of both treatments, and the rest will not purchase any treatment.

Eli Ben Haroosh, Founder & CEO: "Moore's market analysis matches our estimations, Zero Candida is a groundbreaking and game-changing company in the world of women's medicine, and we look forward to be one of the leading companies offering AI-driven, tampon-like device, helping women suffering from VVC ".

Zero Candida announced recently that its shares are now successfully listed on the Frankfurt Stock Exchange (FSE). This listing marks a significant milestone for the Company as it expands its global presence, now cross-listed on both the TSX Venture Exchange and the FSE, providing increased visibility and access to a broader pool of international investors.

To read the full report: https://mma.prnewswire.com/media/2611300/Zero_Candida.pdf

About Zero Candida:

Zero Candida (ZCT) is a publicly traded FemTech company pioneering innovative solutions in women's health. The company is developing an AI-driven, tampon-like device that uses a therapeutic light source with a selected wave-length and intensity to effectively treat the Candida fungus with a demonstrated 99.999% success rate in POC.  Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, with 138 million women affected each year, and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments, since the root cause is poorly understood and addressed. ZCT has successfully completed a safety trial using its pre-clinical device in large animals (sheep), and is finalizing their device for human use in preparation for an upcoming clinical trial, that they secured both funding and agreements with leading hospitals in Israel and Europe for. The Company continues to grow its global patent portfolio with applications filed in the United States , Brazil and Europe , and was recently granted a final patent in South Africa . With hybrid medicine and technology-based diagnostics, ZCT is addressing unmet needs in women's healthcare and expanding access to underserved populations, bringing the field of gynecology into the 21st century. To learn more visit www.zero-candida.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Contacts:

Victoria Gamble
victoria@zero-candida.com
(647) 874 3767

Eli Ben Haroosh
CEO & Founder
info@zero-candida.com

PDF - https://mma.prnewswire.com/media/2611300/Zero_Candida.pdf
Logo - https://mma.prnewswire.com/media/2420533/ZERO_CANDIDA_Logo.jpg

ZERO CANDIDA Logo (PRNewsfoto/ZERO CANDIDA)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/moore-market-analysis-zero-candida-potential-market-will-reach-over-2-billion-by-2030-302366307.html

SOURCE Zero Candida

News Provided by PR Newswire via QuoteMedia

ZCT:CC
The Conversation (0)
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Zero Candida Applies to List its Shares on the TSX Venture Exchange

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology company focused on development and commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor, is pleased to announce that it has filed its application to list the Company's common shares (the " Common Shares ") on the TSX Venture Exchange (the " TSXV "). The application is available under the Company's profile on SEDAR+.

ZERO_CANDIDA_Logo

Zero Candida (formerly 1319743 B .C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company ("ZC" and "Acquisition" respectively). In connection with the completion of the Acquisition, the Company changed its name to Zero Candida Technologies Inc. and split its share capital on a fifty-five thousand five hundred fifty five (55,555) common shares for one (1) common share basis, so that 36 common shares of the Company, without par value which were issued and outstanding immediately before completion of the Acquisition, were split into 2,000,000 common shares without par value. Pursuant to the terms of the Acquisition, the Company issued a total of 17,533,037 common shares (9.6165 common shares in the capital of the Company for each ordinary share in the capital of ZC) (the " Payment Shares "). Following completion of the Acquisition, ZC became a wholly-owned subsidiary of the Company. In addition, in connection with closing of the Acquisition, the Company issued 1,450,643 incentive stock options to employees of ZC (9.6165 incentive Options in exchange for each currently outstanding ZC Option). The terms of the exercise of the Options shall be consistent with the terms of the originally issued underlying ZC securities.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Syntheia Announces Closing of Private Placement

Syntheia Announces Closing of Private Placement

Syntheia Corp. (CSE: SYAI) (Syntheia.ai) (the "Company"), is pleased to announce that further to its press release dated May 29, 2025, it has closed its non-brokered private placement financing for gross proceeds of $411,000 through the issuance of 4,110,000 units (each, a "Unit") at a price of $0.10 per Unit (the "Offering").

Each Unit is comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.13 until June 17, 2027 (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.13 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Private Placement

Syntheia Announces Private Placement

Syntheia Corp. (CSE: SYAI) (Syntheia.ai) (the "Company"), is pleased to announce that it intends to complete a non-brokered private placement financing for gross proceeds of up to $500,000 through the issuance of up to 5,000,000 units (each, a "Unit") at a price of $0.10 per Unit (the "Offering").

Each Unit will be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.13 until the date that is two years from the closing of the Offering (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.13 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Spearmint Proposes Share Consolidation

Spearmint Proposes Share Consolidation

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") announces that it intends to complete a consolidation of its issued and outstanding common shares (the "Shares") on the basis of one new Share (a "Post-consolidated Share") for every ten currently outstanding Shares (the "Consolidation"). The Company also announces it intends to change its name and its trading symbol in connection with the proposed Consolidation.

Completion of the Consolidation, name change and symbol change are subject to approval by the Canadian Securities Exchange (the "CSE"). The effective date of the Consolidation, name change and symbol change will be announced in a subsequent news release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Signs Non-Binding LOI for Call Center Acquisition

Syntheia Signs Non-Binding LOI for Call Center Acquisition

Syntheia Corp. (CSE :SYAI) ("Syntheia" or the "Company") (Syntheia.ai), a leading provider of conversational AI solutions for inbound telephone call management, is pleased to announce that it has entered into a non-binding letter of intent dated May 6, 2025 (the "LOI"), to acquire Beyond The Call Inc. ("BTC"), an arm's length party, and certain of its assets, a call Center in Ontario (the "Proposed Transaction").

Traditional call centers are inefficient legacy businesses with high staff turnover (~ 70%) that have challenges maintaining consistent service quality, maintaining high call volumes, increasing cost of labour along with shortage of qualified labour.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Skyscrapers with logos of Apple, Amazon, Microsoft; "Tech 5" text overlay.

Tech 5: Earnings Season Continues as Meta, Microsoft, Apple and Amazon Report

This week was packed with significant developments across the tech and finance sectors.

Mixed earnings reports from four of the Magnificent Seven revealed the impact tariffs could have on future operations, while Mastercard (NYSE:MA) and Visa (NYSE:V) announced new artificial intelligence (AI) payment initiatives.

Meanwhile, Google (NASDAQ:GOOGL) faced antitrust challenges in court as NVIDIA (NASDAQ:NVDA) navigated changing AI chip export regulations.

Keep reading...Show less

Latest Press Releases

Related News

×